FDA Approves Eli Lilly’s Foundayo (Orforglipron) GLP-1 Pill For Weight Loss

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Used alongside a reduced-calorie diet and increased physical activity, Foundayo is intended to help individuals lose excess body weight and maintain the loss. The medication will be available through LillyDirect, with prescriptions accepted immediately and broader availability through U.S. retail pharmacies and telehealth provider organizations.

In clinical trials, individuals taking the highest dose of Foundayo who remained on treatment lost an average of 27.3 pounds (12.4%), compared to . . .